Depression treatment has long been plagued by inadequate remission rates — roughly half of patients fail first-line antidepressants. The growing psilocybin literature now has enough randomized controlled trial data to warrant pooled analysis, and the results reframe how clinicians and researchers should think about rapid-acting psychedelic interventions for major depressive disorder.
This meta-analysis pooled six RCTs, separating standard-dose psilocybin (approximately 25 mg per session, or weight-adjusted equivalents) from lower-dose regimens. The key signal emerged cleanly in the standard-dose group: a standardized mean difference of −1.05 compared to controls in reducing depressive symptoms, indicating a large effect size by conventional benchmarks. Crucially, remission rates at two to three weeks post-treatment were more than three times higher in the psilocybin arm (RR: 3.38), and response rates remained more than 2.5 times higher at six to twelve weeks — a durability finding that distinguishes psilocybin from many acute interventions. Heterogeneity dropped meaningfully when waiting-list-controlled studies were excluded, leaving two double-blind trials with manualized psychotherapy protocols, suggesting that structured therapeutic support is an important component of efficacy. Low-dose psilocybin showed no comparable benefit, implying a dose-response threshold rather than a smooth continuum.
The findings sit within a fast-maturing literature: COMPASS Pathways and Johns Hopkins have each published Phase IIb or larger RCT data, and this meta-analysis is one of the first to formally quantify durability beyond the immediate post-dosing window. The heterogeneity issue (I² = 75% in the primary analysis) is a legitimate concern and reflects differing control conditions, patient populations, and therapy protocols across trials. All six trials were also relatively small by pharmaceutical standards, meaning effect-size estimates carry wider confidence intervals than phase III drug approvals typically tolerate. The low-dose null finding is scientifically important — it argues against expectation or ritual effects as the primary driver. For health-conscious adults following the psychedelic medicine pipeline, this meta-analysis is confirmatory rather than paradigm-shifting, but it substantially raises the evidentiary floor supporting standard-dose psilocybin as a credible treatment candidate.